Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese Male Subjects

被引：0
|
作者：
Gillen, Michael [1 ]
Miner, Jeffrey N. [2 ]
Valdez, Shakti [3 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Ardea Biosci Inc, Discovery Biol, San Diego, CA USA
[3] Ardea Biosci Inc, San Diego, CA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
193
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
    Shen, Zancong
    Gillen, Michael
    Miner, Jeffrey N.
    Bucci, Gail
    Wilson, David M.
    Hall, Jesse W.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2077 - 2086
  • [2] Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects
    Gillen, Michael
    Shen, Zangong
    Miner, Jeffrey N.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [3] PHARMACOKINETICS, PHARMACODYNAMICS, AND TOLERABILITY OF VERINURAD (RDEA3170), A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN HEALTHY JAPANESE MALE SUBJECTS
    Gillen, M.
    Miner, J. N.
    Valdez, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1366 - 1366
  • [4] Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
    Hall, Jesse
    Gillen, Michael
    Liu, Sha
    Miner, Jeffrey N.
    Valdez, Shakti
    Shen, Zancong
    Lee, Caroline
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1799 - 1807
  • [5] PHARMACOKINETICS, PHARMACODYNAMICS, AND TOLERABILITY OF VERINURAD (RDEA3170), A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN HEALTHY ADULT MALE SUBJECTS
    Gillen, M.
    Shen, Z.
    Miner, J. N.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1366 - 1366
  • [6] Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
    Smith, William B.
    Hall, Jesse
    Berg, Jolene K.
    Kazimir, Michal
    Yamamoto, Amy
    Walker, Susan
    Lee, Caroline A.
    Shen, Zancong
    Wilson, David M.
    Zhou, Dongmei
    Gillen, Michael
    Marbury, Thomas C.
    CLINICAL DRUG INVESTIGATION, 2018, 38 (08) : 703 - 713
  • [7] Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
    William B. Smith
    Jesse Hall
    Jolene K. Berg
    Michal Kazimir
    Amy Yamamoto
    Susan Walker
    Caroline A. Lee
    Zancong Shen
    David M. Wilson
    Dongmei Zhou
    Michael Gillen
    Thomas C. Marbury
    Clinical Drug Investigation, 2018, 38 : 703 - 713
  • [8] Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
    Shen, Zancong
    Rowlings, Colin
    Kerr, Brad
    Hingorani, Vijay
    Manhard, Kimberly
    Quart, Barry
    Yeh, Li-Tain
    Storgard, Chris
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3423 - 3434
  • [9] Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers
    Hall, Jesse
    Gillen, Michael
    Yang, Xiaojuan
    Shen, Zancong
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (02): : 179 - 187
  • [10] Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects
    Yamahira, Naomi
    Frost, Charles
    Fukase, Hiroyuki
    Yu, Zhigang
    Wang, Jessie
    Pursley, Janice
    LaCreta, Frank
    Hiraoka, Masaki
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (07) : 564 - 573
12345